Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

Davidson, Jaime A.

doi:10.4065/mcp.2010.0469

Cited by 40 publications

(22 citation statements)

References 80 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GLP-1 administration also decreases the damage of alveolar capillary basal lamina in rats with spontaneous type 2 diabetes mellitus [183] . The use of these drugs is also associated with improvements in blood pressure, diabetic dyslipidemia and myocardial function [184][185][186] . Therefore, they have a potential role to reduce the cardiovascular risk factors, a major cause of mortality in patients with diabetes.…”

Section: New Strategies To Improve Glycemic Control In Diabetesmentioning

confidence: 99%

Diabetes-related alterations in the enteric nervous system and its microenvironment

Bagyánszki

Bódi²

2012

WJD

View full text Add to dashboard Cite

Gastric intestinal symptoms common among diabetic patients are often caused by intestinal motility abnormalities related to enteric neuropathy. It has recently been demonstrated that the nitrergic subpopulation of myenteric neurons are especially susceptible to the development of diabetic neuropathy. Additionally, different susceptibility of nitrergic neurons located in different intestinal segments to diabetic damage and their different levels of responsiveness to insulin treatment have been revealed. These findings indicate the importance of the neuronal microenvironment in the pathogenesis of diabetic nitrergic neuropathy. The main focus of this review therefore was to summarize recent advances related to the diabetes-related selective nitrergic neuropathy and associated motility disturbances. Special attention was given to the findings on capillary endothelium and enteric glial cells. Growing evidence indicates that capillary endothelium adjacent to the myenteric ganglia and enteric glial cells surrounding them are determinative in establishing the ganglionic microenvironment. Additionally, recent advances in the development of new strategies to improve glycemic control in type 1 and type 2 diabetes mellitus are also considered in this review. Finally, looking to the future, the recent and promising results of metagenomics for the characterization of the gut microbiome in health and disease such as diabetes are highlighted.

show abstract

Section: New Strategies To Improve Glycemic Control In Diabetesmentioning

confidence: 99%

Diabetes-related alterations in the enteric nervous system and its microenvironment

Bagyánszki

Bódi²

2012

WJD

View full text Add to dashboard Cite

show abstract

“…Type 2 diabetes mellitus (DM) is a prevalent disorder that affects children, adolescents, and adults worldwide (1). Diabetic keratopathy is a well-known ocular complication secondary to type 2 diabetes mellitus (2).…”

Section: Introductionmentioning

confidence: 99%

Effect of Stem Cell Therapy on Induced Diabetic Keratopathy in Albino Rat

Zickri¹,

Ahmad²,

Maadawi³

et al. 2012

Int J Stem Cells

View full text Add to dashboard Cite

Background and Objectives: Type 2 diabetes mellitus (DM) is a prevalent disorder. Diabetic keratopathy is a well-known ocular complication secondary to type 2 DM. Topical insulin application did not affect apoptosis and necrosis levels in corneal epithelium. Autologous cell transplantation is not a viable option for diabetic patients with bilateral limbal stem cell deficiency. The present study aimed at assessing the possible effect of hemopoeitic stem cell (HSC) therapy on induced diabetic keratopathy in albino rat. Methods and Results: Fifteen male albino rats were divided into control group of 2 rats, diabetic group of 8 rats receiving single intraperitoneal (IP) injection of 50 mg/kg streptozotocin (STZ). 3 animals were sacrificed 6 weeks following confirmation of diabetes to confirm keratopathy and 5 rats were sacrificed 4 weeks following confirmation of keratopathy. SC therapy group included 5 rats injected with HSCs 6 weeks following confirmation of diabetes and sacrificed 4 weeks following SC therapy. Cord blood collection, stem cells isolation and labeling were performed. Eye specimens were subjected to histological, histochemical, immunohistochemical, morphometric and statistical studies. In diabetic group, the central cornea showed multiple cells with vacuolated cytoplasm and dark nuclei, focal epithelial discontinuity, reduced corneal thickness and less number of layers of corneal and conjunctival epithelia. In stem cell therapy group, few cells with vacuolated cytoplasm and dark nuclei were found in the corneal and conjunctival epithelia with more number of epithelial layers. Conclusions: A definite ameliorating effect of HSC therapy was detected on diabetic keratopathy. The therapeutic cells were effective in limiting corneal epithelial changes.

show abstract

“…4 1,5 Chacune des deux approches pharmacologiques présentent des avantages et des désavantages (Tableau 1), de telle sorte que leur positionnement respectif dans l'arsenal thérapeutique du DT2 mérite d'être discutée. [6][7][8][9] Le but de cet article est de comparer les deux grandes classes de médicaments à effet incrétine, les agonistes des récepteurs du GLP-1, d'une part, et les inhibiteurs de la DPP-4, d'autre part, de façon à donner des arguments au clinicien pour l'aider dans ses choix thérapeutiques en fonction des caractéristiques individuelles du patient DT2.…”

Section: Introductionunclassified

GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?

Scheen

2013

Annales d'Endocrinologie

View full text Add to dashboard Cite

RESUME :Le traitement pharmacologique du diabète de type 2 s'est enrichi, ces dernières années, de l'apport des médicaments à effet incrétine ciblant le glucagon-like peptide-1 (GLP-1). Ces médicaments comprennent soit des agonistes des récepteurs au GLP-1, à courte (injection 1 ou 2 x par jour : exénatide, liraglutide, lixisénatide) ou longue durée d'action (injection hebdomadaire : exénatide à libération prolongée, albiglutide, dulaglutide, taspoglutide) ; soit des agents inhibant l'enzyme inactivant le GLP-1, la dipeptidyl peptidase-4 (DPP-4), actifs par voie orale, les gliptines (sitagliptine, vildagliptine, saxagliptine, linagliptine, nombreuses, à quasi tous les stades du diabète de type 2. Le choix pourra s'orienter selon les caractéristiques cliniques, les objectifs fixés ou simplement les préférences du patient. Mots-clés :

show abstract

Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

Cited by 40 publications

References 80 publications

Diabetes-related alterations in the enteric nervous system and its microenvironment

Diabetes-related alterations in the enteric nervous system and its microenvironment

Effect of Stem Cell Therapy on Induced Diabetic Keratopathy in Albino Rat

GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?

Contact Info

Product

Resources

About